421 related articles for article (PubMed ID: 32017248)
1. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Kyle Jensen M; LaFleur J; Nelson RE
Infect Control Hosp Epidemiol; 2015 Apr; 36(4):438-44. PubMed ID: 25782899
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection.
Jiang M; Leung NH; Ip M; You JHS
PLoS One; 2018; 13(7):e0201539. PubMed ID: 30048534
[TBL] [Abstract][Full Text] [Related]
4. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
Luo Y; Lucas AL; Grinspan AM
Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
6. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
Merlo G; Graves N; Brain D; Connelly LB
J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
[TBL] [Abstract][Full Text] [Related]
9. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
[TBL] [Abstract][Full Text] [Related]
10. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
[TBL] [Abstract][Full Text] [Related]
12. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease.
Cho S; Spencer E; Hirten R; Grinspan A; Dubinsky MC
J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):343-347. PubMed ID: 30320666
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent
Rokkas T; Gisbert JP; Gasbarrini A; Hold GL; Tilg H; Malfertheiner P; Megraud F; O'Morain C
United European Gastroenterol J; 2019 Oct; 7(8):1051-1063. PubMed ID: 31662862
[TBL] [Abstract][Full Text] [Related]
14. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF
Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
[TBL] [Abstract][Full Text] [Related]
16. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
[TBL] [Abstract][Full Text] [Related]
17. Fecal microbiota transplantation for treatment of refractory or recurrent
Lan KY; Le PH; Chiu CT; Chen CC; Yeh YM; Cheng HT; Kuo CJ; Chen CL; Chen YC; Yeh PJ; Chiu CH; Chang CJ
Front Med (Lausanne); 2023; 10():1229148. PubMed ID: 37849493
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.
Aby ES; Vaughn BP; Enns EA; Rajasingham R
Clin Infect Dis; 2022 Oct; 75(9):1602-1609. PubMed ID: 35275989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
